This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Phosphoinositide 3-kinase- β (PI3K β); PTEN (MMAC1; TEP1)	Cell culture and mouse studies suggest targeting PI3K β could help treat patients with PTEN-null tumors. In a panel of 422 human cancer cell lines, cells with mutations in <i>PTEN</i> were more likely to be sensitive to the newly identified PI3K β -selective inhibitor KIN-193 than cells with wild-type <i>PTEN</i> . In mice with PTEN-null tumors, KIN-193 decreased tumor growth compared with vehicle, whereas the drug did not reduce tumor growth in mice that had wild-type PTEN tumors. Next steps include additional testing of KIN-193 in preclinical cancer models.	Unpatented; licensing status not applicable	Ni, J. <i>et al. Cancer Discov</i> ; published online April 12, 2012; doi:10.1158/2159-8290.CD-12-0003 Contact: Jean Zhao, Dana-Farber Cancer Institute, Boston, Mass. e-mail: jean_zhao@dfci.harvard.edu Contact: Nathanael Gray, same affiliation as above e-mail: nathanael_gray@dfci.harvard.edu
<i>SciBX</i> 5(18); doi:10.1038/scibx.2012.462 Published online May 3, 2012				